Proton radiotherapy becomes a new treatment option for age-related macular degeneration in China

China News Online, October 12 (Chen Jing, Sun Guogen, Liang Changhu) The reporter learned on the 12th that Shanghai experts have taken the lead in successfully treating wet fundus macular degeneration with noninvasive and accurate proton technology
.

Age-related macular degeneration, also known as age-related macular degeneration, is an eye disease in which the structure of the macular area is damaged.
It usually progressively damages the patient's vision and even leads to blindness
.
Professor Kong Lin, director of the Head, Neck and Central Nervous Oncology Department of Shanghai Proton Heavy Ion Hospital, said: “Proton radiotherapy provides an ideal treatment option for patients with wet fundus macular degeneration, especially for patients with ineffective drug treatment or unsatisfactory expected results

The reporter learned in an interview that day that with the gradual increase in the number of patients, age-related macular degeneration has become one of the main causes of blindness, seriously affecting the quality of life of middle-aged and elderly patients

As early as 2017, Shanghai Proton Heavy Ion Hospital and the Affiliated Eye, Ear, Nose and Throat Hospital of Fudan University conducted a clinical study on proton therapy for macular degeneration of the fundus
.
The main investigator of the project, Dr.

The reporter was informed on the 12th that Aunt Zhang, the first 79-year-old patient who received proton therapy, told reporters that the entire treatment only requires one proton irradiation and the irradiation time is only 1 minute

During the interview, the reporter learned that Professor Michael F.
Moyers, the chief physicist of the hospital and the director of the Department of Radiological Physics, carried out a clinical study on proton therapy for wet fundus macular degeneration earlier in the world
.
After joining Shanghai Proton Heavy Ion Hospital, he worked with clinical experts in China to work on scientific research on PCV subtype proton therapy.

It is reported that with these important treatment facilities, clinical treatment can further ensure that the prescribed dose of proton heavy ion radiotherapy for tumors, including wet fundus macular degeneration radiotherapy, is given more precise particle beam irradiation, thereby providing better protection for the patient's normal tissues